In the BioHarmony Drug Report Database

"Preview" Icon

Romidepsin

Istodax, Romidepsin (romidepsin) is a protein pharmaceutical. Romidepsin was first approved as Istodax on 2009-11-05. It is used to treat t-cell lymphoma cutaneous and t-cell lymphoma peripheral in the USA. The pharmaceutical is active against histone deacetylase 1. In addition, it is known to target histone deacetylase 4, histone deacetylase 9, histone deacetylase 2, histone deacetylase 8, histone deacetylase 6, histone deacetylase 7, histone deacetylase 3, and histone deacetylase 5. Istodax’s patent is valid until 2021-08-22 (FDA).

 

Trade Name

 

Istodax, Romidepsin
 

Common Name

 

romidepsin
 

ChEMBL ID

 

CHEMBL343448
 

Indication

 

t-cell lymphoma cutaneous, t-cell lymphoma peripheral
 

Drug Class

 

Depsipeptide derivatives

Image (chem structure or protein)

Romidepsin structure rendering